Recombinant Anti-CD3 x Anti-CXCR5 Bispecific Antibody (scFv-Fc) is formed by fusing two different scFv fragments to the hinge and Fc regions, in which the Fc region are engineered by KIH. Two of scFv moiety has the antibody variable domain of either anti-CD3 specificity or anti-CXCR5 specificity, which produces bivalent IgG-like molecules with desired characteristics of intact antibodies. This BsAb can retarget T cells to tumor cells. It is designed for the research of Non-Hodgkin's lymphoma (NHL) therapy.
scFv-based Bispecific Fragments
FuncS; Promising therapeutic agent
Non-Hodgkin's lymphoma (NHL)
CD3; CD3E; CD3e molecule; Cluster of differentiation 3; CD3e molecule, epsilon (CD3-TCR complex); T3E; TCRE; IMD18; T-cell surface glycoprotein CD3 epsilon chain; CD3-epsilon; T-cell surface antigen T3/Leu-4 epsilon chain; CD3e antigen, epsilon polypeptide (TiT3 complex); T-cell antigen receptor complex, epsilon subunit of T3
CXCR5; chemokine (C-X-C motif) receptor 5; BLR1; CD185; MDR15; C-X-C chemokine receptor type 5; CXC-R5; CXCR-5; MDR-15; monocyte-derived receptor 15; Burkitt lymphoma receptor 1, GTP-binding protein; Burkitt lymphoma receptor 1, GTP binding protein (chemokine (C-X-C motif) receptor 5)
Our services and products are only for lab research, not for any diagnostic or therapeutic use.
Welcome! For price inquiries, we will get back to you as soon as possible.
To order, please email